TY - JOUR
T1 - Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGF beta 2 in vascular abnormalization
AU - Dieterich, Lothar C.
AU - Mellberg, Sofie
AU - Langenkamp, Elise
AU - Zhang, Lei
AU - Zieba, Agata
AU - Salomaki, Henriikka
AU - Teichert, Martin
AU - Huang, Hua
AU - Edqvist, Per-Henrik
AU - Kraus, Theo
AU - Augustin, Hellmut G.
AU - Olofsson, Tommie
AU - Larsson, Erik
AU - Soderberg, Ola
AU - Molema, Grietje
AU - Ponten, Fredrik
AU - Georgii-Hemming, Patrik
AU - Alafuzoff, Irina
AU - Dimberg, Anna
PY - 2012/11
Y1 - 2012/11
N2 - Glioblastoma are aggressive astrocytic brain tumours characterized by microvascular proliferation and an abnormal vasculature, giving rise to brain oedema and increased patient morbidity. Here, we have characterized the transcriptome of tumour-associated blood vessels and describe a gene signature clearly associated with pleomorphic, pathologically altered vessels in human glioblastoma (grade IV glioma). We identified 95 genes differentially expressed in glioblastoma vessels, while no significant differences in gene expression were detected between vessels in non-malignant brain and grade II glioma. Differential vascular expression of ANGPT2, CD93, ESM1, ELTD1, FILIP1L and TENC1 in human glioblastoma was validated by immunohistochemistry, using a tissue microarray. Through qPCR analysis of gene induction in primary endothelial cells, we provide evidence that increased VEGF-A and TGF beta 2 signalling in the tumour microenvironment is sufficient to invoke many of the changes in gene expression noted in glioblastoma vessels. Notably, we found an enrichment of Smad target genes within the distinct gene signature of glioblastoma vessels and a significant increase of Smad signalling complexes in the vasculature of human glioblastoma in situ. This indicates a key role of TGF beta signalling in regulating vascular phenotype and suggests that, in addition to VEGF-A, TGF beta 2 may represent a new target for vascular normalization therapy. Copyright (c) 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
AB - Glioblastoma are aggressive astrocytic brain tumours characterized by microvascular proliferation and an abnormal vasculature, giving rise to brain oedema and increased patient morbidity. Here, we have characterized the transcriptome of tumour-associated blood vessels and describe a gene signature clearly associated with pleomorphic, pathologically altered vessels in human glioblastoma (grade IV glioma). We identified 95 genes differentially expressed in glioblastoma vessels, while no significant differences in gene expression were detected between vessels in non-malignant brain and grade II glioma. Differential vascular expression of ANGPT2, CD93, ESM1, ELTD1, FILIP1L and TENC1 in human glioblastoma was validated by immunohistochemistry, using a tissue microarray. Through qPCR analysis of gene induction in primary endothelial cells, we provide evidence that increased VEGF-A and TGF beta 2 signalling in the tumour microenvironment is sufficient to invoke many of the changes in gene expression noted in glioblastoma vessels. Notably, we found an enrichment of Smad target genes within the distinct gene signature of glioblastoma vessels and a significant increase of Smad signalling complexes in the vasculature of human glioblastoma in situ. This indicates a key role of TGF beta signalling in regulating vascular phenotype and suggests that, in addition to VEGF-A, TGF beta 2 may represent a new target for vascular normalization therapy. Copyright (c) 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
KW - brain tumour
KW - vasculature
KW - laser microdissection
KW - microarray
KW - growth factor
KW - angiogenesis
KW - tumour endothelial marker
KW - ENDOTHELIAL GROWTH-FACTOR
KW - TO-MESENCHYMAL TRANSITION
KW - RECEPTOR TYROSINE KINASES
KW - HUMAN PROTEIN ATLAS
KW - STEM-LIKE CELLS
KW - BRAIN-TUMORS
KW - ASTROCYTIC TUMORS
KW - MALIGNANT GLIOMAS
KW - FACTOR-BETA
KW - TGF-BETA
U2 - 10.1002/path.4072
DO - 10.1002/path.4072
M3 - Article
SN - 0022-3417
VL - 228
SP - 378
EP - 390
JO - JOURNAL OF PATHOLOGY
JF - JOURNAL OF PATHOLOGY
IS - 3
ER -